In the current study, we investigated how skeletal stem cells (SSCs) modulate inflammatory osteoclast (OC) formation and bone resorption. Notably, we found that intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and osteoprotegerin (OPG) play a synergistic role in SSC-mediated suppression of inflammatory osteoclastogenesis. The effect of SSCs on inflammatory osteoclastogenesis was investigated using a lipopolysaccharide-induced mouse osteolysis model in vivo and human osteoarthritis synovial fluid (OASF) in vitro. OC formation was determined by tartrate-resistant acid phosphatase staining. Bone resorption was evaluated by microcomputerized tomography, serum C-terminal telopeptide assay, and pit formation assay. The expression of ICAM-1, VCAM-1, and OPG in SSCs and their contribution to the suppression of osteoclastogenesis were determined by flow cytometry or enzyme linked immunosorbent assay. Gene modification, neutralization antibodies, and tumor necrosis factor-α knockout mice were used to further explore the mechanism. The results demonstrated that SSCs remarkably inhibited inflammatory osteoclastogenesis in vivo and in vitro. Mechanistically, inflammatory OASF stimulated ICAM-1 and VCAM-1 expression as well as OPG secretion by SSCs. In addition, ICAM-1 and VCAM-1 recruited CD11b + OC progenitors to proximity with SSCs, which strengthened the inhibitory effects of SSC-derived OPG on osteoclastogenesis. Furthermore, it was revealed that tumor necrosis factor α is closely involved in the suppressive effects. In summary, SSCs express a higher level of ICAM-1 and VCAM-1 and produce more OPG in inflammatory microenvironments, which are sufficient to inhibit osteoclastogenesis in a "capture and educate" manner. These results may represent a synergistic mechanism to prevent bone erosion during joint inflammation by SSCs.
| INTRODUCTION
Skeletal stem cells (SSCs) have been defined as tissue-specific stem cells in skeletons and have been demonstrated to play pivotal roles in maintaining and repairing skeletal tissues. [1] [2] [3] [4] [5] [6] [7] [8] By determining unique cell surface maker profiles and performing rigorous functional characterizations, previous researchers have identified a number of subpopulations of stem and progenitor cells from skeletal tissues, including bone, cartilage, and tendon. [1] [2] [3] [4] [5] [6] [7] [8] Chan et al showed the presence of CD45-Ter119-Tie2-AlphaV+ multipotent stem cells in murine bone and identified cells and factors in the SSC niches that regulate its activity. 2 Another study demonstrated that Gremlin-1 defines a population of osteochondral reticular stem cells in murine bone marrow. Functional assays determined that these cells are needed for bone development, bone remodeling, and fracture repair. 3 Moreover, the recent identification of self-renewing and multipotent SSCs in human bones further validated the presence of endogenous stem cells in skeletal tissue. 8 However, most studies described in these reports focus on SSC' differentiation into osteoblastic lineage cells and their contribution to bone formation. Most importantly, the effect of SSCs on boneresorbing cells, which eat and remodel bones, was overlooked.
Osteoclasts (OCs) are the most potent bone-resorbing cells. [9] [10] [11] By encoding tartrate-resistant acid phosphatase (TRAP) and secreting acid and lytic enzymes, mature, multinucleated OCs produce pits in bone or elephant tusk slices in vitro and degrade bone in vivo. They also promote the release of bone-resorbing substrates, such as serum C-terminal telopeptide (CTX). The process is also accompanied by the expression of osteoclastic genes, including nuclear factor of activated T cells 1 (NF-ATc1), c-Fos, c-Fms, receptor activator of NF-κB (RANK), dendrocyte expressed seven transmembrane protein (DC-STAMP), and cathepsin K. Notably, accumulating studies indicate that OCs are involved in the initiation and progression of inflammatory bone diseases, including osteoarthritis. [9] [10] [11] The increase of proinflammatory cytokines, such as interleukin-1 β (IL-1β), tumor necrosis factor-α (TNF-α), and interleukin-17A (IL-17A), in osteoarthritis synovial fluid (OASF) or subchondral bones lead to overactive OC formation and joint damage. [12] [13] [14] Moreover, cell surface molecules in bone stromal cells typically act as pro-osteoclastic factors. [15] [16] [17] [18] Furthermore, inflammatory osteoclastogenesis was reported to contribute to bone infection-induced osteoporosis. Bacteria-derived molecules, such as lipopolysaccharide (LPS), promote the release of pro-osteoclastic factors and cause systemic bone lesion.
Thus, we suggest that OCs may be a pivotal cell target for the alleviation of inflammatory skeletal lesions, such as osteoarthritis and bone infection. Osteoprotegerin (OPG), a soluble decoy receptor of the receptor activator of NF-κB ligand (RANKL), which is typically produced by connective tissue cells, has been identified as the most potent inhibitor of OC formation. [19] [20] [21] However, this cell-derived OPG typically works in a paracrine manner, which may limit its antiosteoclastic effects. Therefore, it is interesting to investigate how OPG controls osteoclastogenesis in skeletal tissues.
We have pursued the identification of SSCs and the exploration of SSC-mediated regulation over the past decade. [22] [23] [24] Our previous studies revealed the pivotal role of SSCs in controlling the inflammatory response. We showed that intravenous infusion of murine SSCs could alter the phenotype and function of splenic lymphocytes, which ameliorate the inflammatory tissue damage. 25 Further investigation demonstrated that murine SSCs alter the migratory property of T and dendritic cells and delay the development of murine lethal acute graftversus-host disease. 26 Our recent study showed that SSCs are capable of attenuating poly (lactic-co-glycolic) acid-induced inflammatory responses by inhibiting host dendritic cell maturation and function. 27 Given the fundamental role of OCs in inflammatory bone lesions and the potent immunoregulatory properties of SSCs, an effective strategy for alleviating inflammatory bone diseases may be via targeting OCs. In the present study, we explored the effects of SSCs on inflammatory osteoclastogenesis and the subsequent bone resorption. Moreover, the cellular and molecular mechanisms underlying the capacity of SSCs to regulate inflammatory osteoclastogenesis were also investigated. 
| MATERIALS AND METHODS

| Animals
| Osteoarthritis patients and samples
The synovial fluid from osteoarthritis patients (OASF) is a potent inflammatory mediator, which includes numerous inflammatory cytokines and has been reported to promote osteo-chondral lesion in osteoarthritis. In the current study, OASF was used to mimic the joint microenvironments of osteoarthritis and investigate the potential role of SSCs in inflammatory osteoclastogenesis. Briefly, human OASF was aspirated from the knee joints of 10 patients with osteoarthritis (OA) (3 males and 7 females, average age 60.7 years, average BMI 25.3 kg/m, average disease duration 6.8 years) (Table S1 ). The OASF was further purified by centrifugation at 3000 revolutions per minute for 15 minutes, and the supernatants were harvested for further investigation. All patients met the American College of Rheumatology criteria for the classification of knee OA. 28, 29 They were classified as Kellgren-Lawrence grade 3 or 4, with synovial cavity effusion of grade 2 or 3 according to their whole-organ magnetic resonance imaging score (WOMRS), (grade 0, normal; grade 1, less than 33% of maximum potential distension; grade 2, 33% to 66% of maximum potential distension; and grade 3, greater than 66% of maximum potential distension). 28, 29 The exclusion criteria included a history of inflammatory arthritis, previous knee surgery or knee injection, or metastatic cancer. Ethics approval was obtained from the hospital Research Ethics Committee, and participant consent was acquired prior to the collection of samples.
| SSC preparation
In the current study, murine SSCs were cultured from mouse long bones according to a method we previously established with minor revision. 23 Briefly, femurs and tibiae from 2-week-old C57BL/6 mice (n = 20) were dissected, and the bone marrow cells were flushed out. The whole long bones were chopped and then digested by collagenase II (Sigma, 3050 Spruce Street, Saint Louis, MO 63103, USA, 0.1% vol/vol) at 37 C for 1 hour. The bone chips were cultured in minimum essential medium eagle, alpha modification (α-MEM; Invitrogen, Carlsbad, California) supplemented with 10% fetal bovine serum (FBS; Hyclone, Logan, Utah).
The adherent cells at passages 3-6 were used for in vivo and in vitro experiments unless otherwise described.
To investigate the underlying mechanisms of SSCs in inflammatory osteoclastogenesis, the expression of OPG was genetically knocked down in SSC-like cells (C3H10T1/2, ATCC) by using commercial lentiviral products (Shanghai Genechem Co., Ltd). The ICAM-1 high SSCs (C3H10T1/2-ICAM-1 overexpression) and VCAM-1 high SSCs (C3H10T1/2-VCAM-1 overexpression) previously prepared and maintained in our lab were also used in the current study. 30, 31 
| SSC infusion of a mouse inflammatory bone resorption model
LPS infusion into mice typically causes inflammatory responses and overactive osteoclastogenesis. [32] [33] [34] To investigate the effects of SSCs on inflammatory osteoclastogenesis in vivo, SSCs were administered to mice via the tail vein. Briefly, LPS was administered to 8-week-old Balb/c mice via a single intraperitoneal injection of 200 μg in 100 μL PBS per mouse (LPS mice). Shortly afterwards, graded doses of SSC (0, 1 × 10 5 and 5 × 10 5 SSC per mouse) were administered to the mice via tail vein injection. For mechanistic investigation, ICAM-1 high SSCs, VCAM-1 high SSCs, and OPG knocked-down SSCs (OPG low SSCs) were intravenously administered to the LPS mice (5 × 10 5 SSC per mouse, n = 6), respectively. The control group mice received PBS (PBS mice) instead of SSCs.
For the in situ osteoclastogenesis assay, eight mice per group were sacrificed at day 7 post SSC injection, and the murine tibias were harvested (n = 8). The specimens were fixed in 10% neutral buffered formalin, imbedded in paraffin, demineralized in edetic acid disodium salt decalcified solution, and cut into 5-μm-thick sections. OC formation was determined by TRAP staining. For the CTX assay, the sera were obtained from six mice per group 21 days after SSC injection (n = 4). All plasma samples were freshly isolated by centrifugation. To detect the mRNA expression of osteoclastic genes in mice, six mice per group were sacrificed 5 days post SSC infusion (n = 4), and bone marrow cells were harvested by centrifugation for further determination via real-time quantitative polymerase chain reaction (RT-qPCR).
| Micro computerized tomography (μCT) analysis
Murine femurs were harvested 21 days after SSC injection (n = 4).
The femurs were then fixed overnight in 10% neutral buffered formalin, washed twice in PBS, and stored in 70% ethanol at 4 C for further analysis. μCT scanning and analysis were performed by using a Scanco μCT-40 (Scanco Medical). The bones were scanned at a resolution of 8 μm, and reconstruction of three-dimensional (3D) images was performed using a standard convolution back-projection. The bone volume/tissue volume ratio (BV/TV) was calculated by measuring 3D distances directly in the trabecular network.
| TRAP staining
TRAP is a specific marker for osteoclast formation. 33 
| SSC-involved osteoclast generation in the presence of human OASF
Murine monocytes were purified from the bone marrow mononuclear cells of 8-week-old BALB/c mice using the magnetic-activated cell sorting (MACS) CD11b + Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany). To generate osteoclasts, murine monocytes were cultured in 48-well-plates (2 × 10 3 monocytes per well) with the addition of human OASF (20% vol/vol). To investigate the effect of SSCs on osteoclastogenesis, SSCs (2 × 10 3 SSC per well) were added into the in vitro OC culture system. To further validate the suppressive effect of SSCs, pro-osteoclastic cytokines, murine macrophage colony-stimulating factor (M-CSF, 20 ng/mL) and murine RANKL (20 ng/mL) were added to the previously described in vitro culture system. OC formation was determined by TRAP staining at day 5 after initial culture, and the osteoclasts were counted under a light microscope (n = 6).
To exclude the possibility that osteoclastic genes decrease due to a relatively decreased number of OCs among the mixed cell population for gene analysis, the OCs were generated by advantage of a 0.4-μmpore-size membrane Transwell system (Coring) as previously employed by our group. Briefly, SSCs were cultured on the reverse side of the chamber membrane, while CD11b + OC precursors were seeded on the upper side of the chamber membrane. After coculture for 5 days, the OCs were harvested from the upper chamber without SSC contamination (n = 4). The osteoclastic genes in the cocultured SSCs/OCs or OCs generated in the Transwell system were assayed, respectively.
To mechanistically investigate the suppressive effects of SSCs on OAS-induced osteoclast formation, neutralization antibodies, including anti-TNF-α, anti-IFN-γ, anti-IL-17A, anti-M-CSF, and anti-IL-6, were added to the SSC/OASF culture system (200 ng/mL). The TRAP + osteoclasts were counted (n = 6).
| Bone resorption pit formation assay
The bone-resorbing activity of OCs was assessed using sterile elephant tusk slices prepared from discarded elephant tusks (Osteosite Dentine Discs, IDS Ltd). The tusk slices (5 mm diameter and 0.3 mm thickness, n = 6) were washed three times with culture medium before they were carefully placed at the bottom of the wells of a 48-well cell culture plate. SSCs were seeded onto each slice at a density of 1 × 10 4 per well. The murine CD11b + monocytes were added after 24 hours at a density of 1 × 10 4 per well. The OC culture medium (20 ng/mL M-CSF and 20 ng/mL RANKL) supplemented with 10% (vol/vol) OASF was changed every 2 days. The culture was maintained for 3 weeks. The cells on the tusk slices were removed via ultrasonic treatment. The cellfree tusk slices were stained with Toluidine blue to detect resorption pits under a light microscope. The percentage of resorption pits was estimated using the computerized image analysis software Image-Pro Plus (IPP) 6.0. The cell culture medium was harvested from the dentine slice-based resorption system for CTX assay (n = 6).
| CTX assay
CTXs are bone collagen degradation products released into the circulation during bone resorption, and an enhancement of osteoclastic activity causes the accumulation of CTXs in vivo. 33 Thus, bone resorptions were further evaluated by measuring the serum levels of CTX in mice. In the current study, the CTX levels in the murine serum and cell culture supernatant were determined by using a commercial kit on serum samples according to the manufacturer's instructions (Nordic Bioscience Diagnostics). All plasma samples and cell culture supernatant were freshly isolated by centrifugation and filtered to deplete cellular components. were added into the SSC/OC culture system (200 ng/mL). The OPG in the culture medium of each group were detected by ELISA assay.
| Effect of OASF on cell surface molecules and OPG by SSCs
The ratios of ICAM-1-or VCAM-1-expressing SSCs in each group were determined by flow cytometry.
| SSC/OC progenitor adhesion assay
The SSC/OC progenitor adhesion assay was performed according to a published protocol with minor revision. 35 Briefly, SSCs were seeded into a six-well-plate at a density of 5 × 
| Generation of TNF-α deficient inflammatory serum using TNF-α-KO mice
To further investigate the role of TNF-α in SSC-mediated suppression of inflammatory osteoclastogenesis, LPS were intraperitoneally administered to 8-week-old TNF-α KO mice and their wild-type counterparts by a single injection of 200 μg in 100 μL PBS per mouse. After 3 days, the mice were sacrificed, and the serum was generated from peripheral blood by centrifugation at 3000 revolutions per minute for 15 minutes. The serum was filtered using a 0.4-μm-pore-size membrane to remove the possible cellular contamination before addition to the SSC/OC coculture system (20%, vol/vol).
F I G U R E 2 Skeletal stem cells (SSCs) inhibited osteoclastic differentiation and pit formation in the presence of human osteoarthritis synovial fluids (OASF). A, Murine
CD11b + bone marrow monocytes were cultured in 48-well-plates (2 × 10 3 monocytes per well) in the presence of human OASF (20% vol/vol). The osteoclasts in culture plates were determined by tartrate-resistant acid phosphatase (TRAP) staining after 7 days. TRAP+ multinucleated cells (3 or more nuclei) were manually counted under a light microscope. In some groups, SSCs (2 × 10 3 SSCs per well) were added in the previously described in vitro OC culture system. The results of TRAP staining showed that SSCs inhibited OASF-induced osteoclastogenesis. To further validate the suppressive effect of SSCs, pro-osteoclastic cytokines murine M-CSF (20 ng/mL) and murine RANKL (20 ng/mL) were added into the previously described in vitro culture system, which yielded more osteoclasts in plate wells as expected. Notably, SSCs (2 × 10 3 SSCs per well) exhibited strong suppressive effects on osteoclastogenesis that were induced by both OASF and pro-osteoclastic cytokines. Bars represent 200 μm. B, **P < .01 compared with no-SSC control, n = 6. C, In addition, the fit formation assays were performed on the dentine slices (diameter 5 mm, thickness 0.3 mm) by culturing osteoclasts in four groups as previously described for 3 weeks. The pits were determined by Toluidine blue staining. D, The percentage of resorption pits was estimated using computerized image analysis software. SSCs significantly suppressed pit formation induced by inflammatory osteoclastogenesis in vitro. *P < .05; **P < .01 compared with no-SSC control, n = 6. E, Furthermore, the CTX in culture medium was detected after 3 weeks to validate the suppressive effects of SSCs on inflammatory resorptions. *P < .05; **P < .01 compared with the no-SSC control, n = 6. F, Moreover, the osteoclastic genes in the SSC/osteoclast system (0, 1 ×10 5 , 5 × 10 5 SSC, and 1 × 10 5 CD11b + monocytes per well of six-well plates) were determined at day 5. SSC significantly suppressed the expression of osteoclastic markers in the presence of human OASF in an SSC dose-dependent manner. *P < .05, compared with human OASF group, n = 6
| Statistical analysis
Data are represented as the mean values with standard deviations. Statistical significance was analysed using Student's t test and one way ANOVA. P values less than 0.05 were considered to be significant.
| RESULTS
| Intravenous infusion of SSCs suppressed murine inflammatory osteoclastogenesis and bone resorption
Approximately 5 × 10 7 cells (passage 4) were harvested in each mouse before the experiments. As shown in Figure 1A suppressive effect was SSC dose-dependent ( Figure 1F ) (*P < .05; **P < .01). Therefore, these results suggest that SSC infusion significantly suppresses OC formation and bone resorption in proinflammatory microenvironments in vivo, but it does not affect the osteoclastic activity in noninflammatory mice.
| SSCs inhibited OC differentiation and pit formation in the presence of human OASF
SSCs and CD11b + monocytes were cocultured in the presence of OASF (10%, vol/vol) with/without M-CSF (20 ng/mL) and RANKL (20 ng/mL) to investigate the influence of OASF on SSC-mediated osteoclastogenesis. After culturing for 9 days, the cells were stained, and the TRAP+ multinucleated cells were counted. The results of the SSC-involved OC generation experiments showed that SSCs inhibit OC formation in the presence of human OASF (Figure 2A ,B) (**P < .01). In addition, they inhibited OC formation in osteoclastic induction medium (Figure 2A and an anti-OPG-neutralization antibody ( Figure 3F ) when the SSCs were cocultured with monocytes. We found that the in vitro OC formation in the SSC/OC coculture system was significantly rescued, which demonstrates that OASF-induced OPG secretion in SSCs significantly contributed to the osteoclastic suppression ( Figure 3E ,F) (*P < .05).
Increasing evidence has demonstrated that highly expressed ICAM-1 and VCAM-1 contribute to the progression of inflammatory diseases, including osteoarthritis. 36, 37 In the current study, we found that incubation with human OASF-induced high expressions of ICAM-1 and VCAM-1 by SSCs ( Figure 4A ). Functionally, we used blocking antibodies against ICAM-1 and VCAM-1 to directly test whether ICAM-1 and VCAM-1 in SSC mediate OC precursor adhesion. As CD11b + cells represent a pivotal subpopulation of OC precursors, we identified a CFSE + CD11b + cell proportion to evaluate the adhesion capacity of SSCs. As shown in Figure 4B To detect synergistic effects of the adhesion molecules and OPG in SSC-mediated OC suppression in vivo, we infused OPG knock-down SSCs, as well as ICAM-1 high and VCAM-1 high SSCs into LPS mice individually. The results of the murine tibia TRAP staining showed that SSC-induced OPG deficiency led to an increased number of OC in situ ( Figure 5A ,B) (*P < .05). In addition, we found that SSC-mediated osteoclast suppression was remarkably enhanced when ICAM-1 or VCAM-1 were genetically overexpressed ( Figure 5C 
| DISCUSSION
In the current study, we found that SSCs inhibit inflammatory osteoclastogenesis via the concerted action of OPG and cell adhesion molecules in vivo and in vitro. Moreover, we demonstrated that TNFα is indispensable for the suppressive effects.
SSCs are endogenous stem cells in skeletal tissues. Increasing evidence has demonstrated that SSCs are closely involved in bone homeostasis. [1] [2] [3] [4] [5] [6] [7] [8] 38, 39 These cells respond to tissue stress and migrate to sites of injury, supplying new osteoblasts during fracture healing. 40 In addition, SSCs are capable of homing back to the bone marrow after intravenous infusion and providing a supportive environment for hematopoiesis. 41 Notably, our previous studies show that a subpopulation of SSCs remain present in murine bone, and further investigations demonstrated that SSCs play a role as a pivotal regulator in inflammatory responses in vitro and in vivo. [25] [26] [27] In the current study, SSCs were harvested from whole long bones of mice to include more SSC populations. Here, we identified a novel function SSCs in inhibiting inflammatory osteoclastogenesis using an LPS mouse model and human OASF, which deepens the understanding of skeletal biology in bone diseases.
Accumulated studies have demonstrated that ICAM-1 and VCAM-1 are critically involved in various inflammatory pathological diseases, such as osteoarthritis. 36, 37 ICAM-1 is highly expressed in OC precursors and stromal cells, including synoviocytes, osteoblasts and periodontal ligament fibroblasts, in osteoarthritis. Although the role of ICAM-1 in osteoclastogenesis has been widely reported, most previous studies have suggested ICAM-1 is a pro-osteoclastic molecule. 36 The expression of ICAM-1 by OC precursors increases during OC formation, and blocking ICAM-1 in OC precursors decreased the number of osteoclasts formed. 42 In addition, ICAM-1-expressing osteoblasts have been proven to support OC formation, and osteoblasts that lack ICAM-1 do not possess this capacity. 36 Further studies show that ICAM-1 is highly expressed in damaged articular and meniscal cartilage in human OA. 36 VCAM-1 is also viewed as an inflammatory mediator in the pathologic process of bone disease. A clinical study concluded that the level of soluble VCAM-1 emerged as a strong and independent predictor of the risk of hip and knee joint replacement due to severe OA. 43 Another study demonstrated VCAM-1 is highly expressed in RA whole-tissue synovial explants. 44 To Interestingly, Ren et al reported that when mesenchymal stromal cells (MSCs) were cocultured with activated T cells, they significantly upregulated the adhesive capability of T cells. 45 Moreover, the greater the expression of ICAM-1 and VCAM-1 by MSCs is associated with the greater the immunosuppressive effects exhibited by MSCs. 46 Further study showed that T cell-derived inflammatory cytokines induce the expression of ICAM-1 and VCAM-1. Moreover, blocking cell adhesion molecules with neutralization antibodies remarkably decreased the immunosuppressive capacity. These findings demonstrated that inducible ICAM-1 and VCAM-1 were able to recruit more T cells to the proximity of MSCs, which promoted MSC-mediated immunosuppression. 35 Therefore, the work of Ren et al suggested that close proximity is pivotal for MSC-derived factors to modulate T cell proliferation and other immune responses, which indicated a novel function of ICAM-1 and VCAM-1 in immunoregulation by MSCs. 45, 46 In the current study, we were greatly interested in whether these molecules were involved in SSC-mediated osteoclastic suppression. We found that ICAM-1 and VCAM-1 play pivotal roles in osteoclastic regulation by SSCs in a similar manner to that of immunoregulation by MSCs.
Induced by TNF-α in OASF, the SSCs highly expressed ICAM-1 and VCAM-1. An adhesion assay indicated that the upregulated adhesion molecules captured more CD11b + OC precursors. Most importantly, TNF-α promoted-SSCs secreted more OPG. As previously established, OPG is a decoy receptor for RANKL and has been identified as a key suppressor of osteoclastogenesis. Therefore, we suggest that SSCs capture more OC precursors and enable OPG to work in proximity. To validate this idea, the expression of OPG by SSCs was inhibited by both RNAi and OPGneutralization antibody. The suppressive effect of osteoclastogenesis was remarkably decreased when OPG was blocked. The data strongly support the hypothesis that SSCs inhibit inflammatory OC formation in a "capture and educate" manner. Moreover, SSC administration did not significantly affect osteoclast formation in PBS mice, which suggested that SSCs may modulate inflammatory osteoclastic activity in a way that is different from that in noninflammatory microenvironments.
Our findings have important implications for the treatments of bone disease. Although many types of stem cells have been used to treat bone diseases in previous decades, the emergence of SSCs brings a new choice for therapy. The antiosteoclastic capacity of SSCs may be useful in the treatment of inflammatory joint diseases. On the other hand, in addition to the therapeutic effects of exogenous SSCs in skeletal repair, endogenous SSCs may be a novel cell target to reduce osteoclastic resorption in bone disease. 45, 46 Nevertheless, we must acknowledge several limitations in our study. First, a bone resorption assay is important to evaluate osteoclastogenesis. 9, 47 Determining the roughness of the dentin slices by profilometry in further investigations may be helpful to measure the resorption pit. 48 Second, the molecular mechanisms that control the expression of ICAM-1 and VCAM-1, as well as OPG expression by SSCs should be clarified in future investigations. Third, additional explorations are needed to determine whether other factors contribute to SSC-mediated suppression of inflammatory osteoclastogenesis in vitro and in vivo, and high-throughput assays may be helpful to address this issue.
Fourth, the number of human OASF samples used in the current study is relatively small, and the clinical sample size should be enlarged to reinforce the findings in further studies.
| SUMMARY
In the present study, we reported a new role for SSCs in the suppression of inflammatory osteoclastogenesis. In addition, our study shows synergistic mechanisms that limit bone erosion during joint inflammation by SSCs. Importantly, a comprehensive analysis of SSCs in human bone diseases is needed to further investigate and clarify these results.
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